Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Epigenomic Profiling of cirDNA in Colorectal Cancer
EF 2012-13
Résumé
Colorectal cancer is the third most common cancer and the second common cancer-related cause of death in Canada. It is estimated for 2012 that 23,300 Canadians will be diagnosed with colorectal cancer and 9,200 will die of it. Early detection of colorectal cancer increases treatment options and significantly improves a patient's chances of survival. Current detection tests, such as colonoscopy, are not applicable in screening programs because they expensive and are associated to serious complications. Other screening tests, such as fecal occult blood test, are often unreliable due to low accuracy and frequently lead to missed diagnoses. There is a need for new methods to reliably detect colorectal cancer in its early stages of development.
We believe that such a test may be developed using a blood sample. During the growth of a tumour, from its earliest stages, some malignant cells die, and the contents of such cells are released into the blood stream. It has been known for some time that cancer cells exhibit numerous genetic and epigenetic changes. Epigenetic changes are chemical modifications to the structure of the genes that are used normally regulate (turn on an off) the gene. The observation that DNA carrying aberrant epigenetic signatures appears in the blood stream of cancer patients can be used to develop epigenetic markers for early detection of cancer.
We propose to scan epigenetic profiles of DNA floating in blood samples from colorectal cancer patients and controls in order to detect cancer-specific epigenetic differences. This first genome-wide scan for epigenetic modification in cell-free floating DNA in blood may provide novel, non-invasive markers, with the potential for translation into clinical practice.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
274472
Name
Kwan Andrew
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Epigenomic Profiling of cirDNA in Colorectal Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Biomarker Discovery; Colorectal Cancer; Dna Methylation; Dna Modification; Early Diagnosis; Epigenetic Signature; Epigenomics; Low Invasiveness; Microarray; Plasma Circulating Dna
Abstract
Colorectal cancer is the third most common cancer and the second common cancer-related cause of death in Canada. It is estimated for 2012 that 23,300 Canadians will be diagnosed with colorectal cancer and 9,200 will die of it. Early detection of colorectal cancer increases treatment options and significantly improves a patient's chances of survival. Current detection tests, such as colonoscopy, are not applicable in screening programs because they expensive and are associated to serious complications. Other screening tests, such as fecal occult blood test, are often unreliable due to low accuracy and frequently lead to missed diagnoses. There is a need for new methods to reliably detect colorectal cancer in its early stages of development.
We believe that such a test may be developed using a blood sample. During the growth of a tumour, from its earliest stages, some malignant cells die, and the contents of such cells are released into the blood stream. It has been known for some time that cancer cells exhibit numerous genetic and epigenetic changes. Epigenetic changes are chemical modifications to the structure of the genes that are used normally regulate (turn on an off) the gene. The observation that DNA carrying aberrant epigenetic signatures appears in the blood stream of cancer patients can be used to develop epigenetic markers for early detection of cancer.
We propose to scan epigenetic profiles of DNA floating in blood samples from colorectal cancer patients and controls in order to detect cancer-specific epigenetic differences. This first genome-wide scan for epigenetic modification in cell-free floating DNA in blood may provide novel, non-invasive markers, with the potential for translation into clinical practice.
Competitiondate
201211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kwan, Andrew
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~